Skip to main content
SpringerLink
Log in

Increased Levels of Urinary Albumin: A Cardiovascular Risk Factor and a Target for Treatment

  • Chapter
Cardiorenal Syndrome

  • 1066 Accesses

Abstract

Excretion of albumin in the urine is highly variable, ranging from nondetectable quantities to grams. Increased levels of albuminuria are highly prevalent in healthy individuals and even more so in hypertensive and diabetic populations. The variable excretion of albumin in the urine is related to the risk for the individual to develop cardiovascular disease (CVD): absence or very low levels of albuminuria is associated with low risk, whereas the risk continuously increases (with no thresholds) with increasing amount of urinary albumin. The predictive power of urinary albumin levels for CVD risk is independent of other CVD risk factors. Leakage of albumin appears to be associated with a defect in vascular permeability, most likely caused by a defect in the glycocalyx layer. This defect appears to be not only present in the kidneys but also in other vascular beds, providing a potential explanation as to why increased albuminuria not only predicts renal disease risk but also CVD risk. Treatments that lower albuminuria are associated with cardiovascular protection, as demonstrated in randomized controlled trials of diabetic as well as hypertensive patients. There is preliminary evidence that albuminuria lowering also protects healthy individuals with elevated albumin excretion rates. In conclusion, albuminuria appears to be a sensitive marker for the susceptibility of an individual to develop CVD. Lowering albuminuria appears to be associated with cardiovascular protection._It may therefore be a suitable target for early primary prevention using cardiovascular protective therapy regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Levey AS, Eckardt KU, Tsukamoto Y et al (2005) Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67:2089–2100

    Article  PubMed  Google Scholar 

  2. Zandi-Nejad K, Eddy AA, Glassock RJ et al (2004) Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int Suppl 92:S76–89

    Article  Google Scholar 

  3. Bakker SJ, Gansevoort RT, de Zeeuw D (2009) Albuminuria: what can we expect from the determination of nonimmunoreactive albumin? Curr Hypertens Rep 11:111–117.

    Article  CAS  PubMed  Google Scholar 

  4. Witte EC, Lambers Heerspink HJ, de Zeeuw D et al. (2009) First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol.20:436–443

    Article  CAS  PubMed  Google Scholar 

  5. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D et al (2008) Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 168:897–905

    Article  PubMed  Google Scholar 

  6. Brinkman JW, de Zeeuw D, Gansevoort RT (2007) Prolonged frozen storage of urine reduces the value of albuminuria for mortality prediction. Clin Chem. 53:153–154

    Article  CAS  PubMed  Google Scholar 

  7. Lambers Heerspink HJ, Nauta FL, Van der Zee C et al (2009) Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus. Diabet Med 26:556–559

    Article  CAS  PubMed  Google Scholar 

  8. de Zeeuw D, Parving HH, Henning RH (2006) Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 17:2100–2105

    Article  PubMed  Google Scholar 

  9. Brantsma AH, Bakker SJ, de Zeeuw D (2006) Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol 17:331–335

    CAS  PubMed  Google Scholar 

  10. Brantsma AH, Bakker SJ, Hillege HL et al (2005) Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 28:2525–2530

    Article  CAS  PubMed  Google Scholar 

  11. Haraldsson B, Nystrom J, Deen WM (2008) Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88:451–487

    Article  CAS  PubMed  Google Scholar 

  12. Satchell SC, Tooke JE (2008) What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 51(5):714–725

    Article  CAS  PubMed  Google Scholar 

  13. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356–360

    Article  CAS  PubMed  Google Scholar 

  14. Dinneen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in noninsulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157:1413–1418

    Article  CAS  PubMed  Google Scholar 

  15. Weir MR (2004) Microalbuminuria in type 2 diabetes: an important, overlooked cardiovascular risk factor. J Clin Hypertens 6:134–143

    Article  Google Scholar 

  16. Yuyun MF, Dinneen SF, Edwards OM et al (2003) Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med 20:277–282

    Article  CAS  PubMed  Google Scholar 

  17. Kannel WB, Stampfer MJ (1984) The prognostic significance of proteinuria: the Framingham Study. Am Heart J 108:1347–1352

    Article  CAS  PubMed  Google Scholar 

  18. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S et al (1999) Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19:1992–1997

    CAS  PubMed  Google Scholar 

  19. Hillege HL, Fidler V, Diercks GFH et al (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation 106:1777–1782

    Article  CAS  PubMed  Google Scholar 

  20. Romundstad S, Holmen J, Kvenild K et al (2003) Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis 42:466–473

    Article  PubMed  Google Scholar 

  21. Yuyun MF, Khaw KT Luben R et al (2004) Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 33:189–198

    Article  PubMed  Google Scholar 

  22. Arnlov J, Evans JC, Meigs JB (2005) Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112:969–975

    Article  PubMed  Google Scholar 

  23. Olsen MH, Wachtell K, Ibsen H et al (2006) Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: The LIFE Study. J Hypertension 24:775–781

    Article  CAS  Google Scholar 

  24. Klausen K, Borch-Johnsen K, Jensen G et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35

    Article  CAS  PubMed  Google Scholar 

  25. Ratto E, Leoncini G, Viazzi F et al (2006) Microalbuminuria and cardiovascular risk assessment in primary hypertension: should threshold levels be revised? Am J Hypertens. 19:728–734

    Article  CAS  PubMed  Google Scholar 

  26. Bigazzi R, Bianchi S, Baldari D et al (1998) Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16:1325–1333

    Article  CAS  PubMed  Google Scholar 

  27. Jensen JS, Feldt-Rasmussen B, Strandgaard S (2000) Arterial hypertension, micro-albuminuria, and risk of ischemic heart disease. Hypertension 35:898–903

    CAS  PubMed  Google Scholar 

  28. Wachtell K, Ibsen H, Olsen MH et al (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139:901–906

    PubMed  Google Scholar 

  29. Gerstein HC, Mann JF, Yi Q et al (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426

    Article  CAS  PubMed  Google Scholar 

  30. Brantsma AH, Bakker SJ, Hillege HL et al (2008) Cardiovascular and renal outcome in subjects with K/DOQI stage 1–3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant. 2008 23:3851–3858

    Article  CAS  PubMed  Google Scholar 

  31. Ninomiya T, Perkovic V, de Galan BE et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20:1813–1821

    Article  PubMed  Google Scholar 

  32. Tonolo G, Ciccarese M, Brizzi P et al (1997). Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20:1891–1895

    Article  CAS  PubMed  Google Scholar 

  33. Nakamura T, Ushiyama C, Hirokawa K et al (2002) Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21:449–454

    Article  Google Scholar 

  34. Gambaro G, Kinalska I, Oksa A et al (2002) Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 13:1615–1625

    Article  CAS  PubMed  Google Scholar 

  35. Agarwal R, Acharya M, Tian J et al (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int._68:2823–2828

    Article  CAS  PubMed  Google Scholar 

  36. Parving HH, Lehnert H, Brochner-Mortensen J et al (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878

    Article  CAS  PubMed  Google Scholar 

  37. Asselbergs FW, Diercks GFH, Hillege H et al (2004) Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110:2809–2816

    Article  CAS  PubMed  Google Scholar 

  38. de Zeeuw D, Remuzzi G, Parving HH et al (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110(8):921–927

    Article  PubMed  Google Scholar 

  39. de Jong PE, Curhan G (2006) Screening, monitoring and treatment of albuminuria — public health perspectives. J Am Soc Nephrol 17(8):2120–2126

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmachology, University Medical Center, Groningen, Netherlands

    Dick de Zeeuw & Hiddo J. Lambers Heerspink

Authors
  1. Dick de Zeeuw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiddo J. Lambers Heerspink
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

    Adel E. Berbari

  2. Clinica Medica Department of Clinical Medicine and Prevention, University of Milano-Bicocca San Gerardo Hospital, Monza, Milan, Italy

    Giuseppe Mancia

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Italia

About this chapter

Cite this chapter

de Zeeuw, D., Lambers Heerspink, H.J. (2010). Increased Levels of Urinary Albumin: A Cardiovascular Risk Factor and a Target for Treatment. In: Berbari, A.E., Mancia, G. (eds) Cardiorenal Syndrome. Springer, Milano. https://doi.org/10.1007/978-88-470-1463-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1463-3_8

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1462-6

  • Online ISBN: 978-88-470-1463-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation